

| | | | |
|--------------------------|--|--------------------|--------------------|
| | | EMLc | ATC codes: L01CB01 |
| Indication | Ewing sarcoma of bone and articular cartilage of unspecified sites | ICD11 code: 2C22.Z | |
| INN | Etoposide | | |
| Medicine type | Chemical agent | | |
| List type | Complementary (EML) (EMLc) | | |
| Formulations | Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule ; 100 mg in vial powder for injection (as phosphate) Oral > Solid: 100 mg capsule ; 50 mg capsule | | |
| EML status history | First added in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2023 (TRS 1049) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic alternatives | The recommendation is for this specific medicine | | |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  | | |
| Tags | Cancer | | |
| Wikipedia | Etoposide  | | |
| DrugBank | Etoposide  | | |

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of etoposide (Powder for injection: 100 mg (as phosphate) in vial) to the EML and EMLc.

Expert Committee report 

